Global /Japan /Healthcare /Biotechnology /4263

SUSMED,Inc.

4263

• TSE: 4263 • Delayed

916JPY -4.1%

5.72 USD

As of 6 June 2026, SUSMED,Inc. has a market cap of $96.24M USD, ranking #25850 globally and #2284 in Japan. It ranks #2320 in the Healthcare sector, and #447 in the Biotechnology industry.

Global Rank

25850

Country Rank

2284

Sector Rank

2320

Industry Rank

447

Key Stats

Market Cap

$96.24MUSD

15.4B JPY

Enterprise Value

$71.13MUSD

11.39B JPY

Revenue (TTM)

$3.0MUSD

480.0M JPY

EBITDA (TTM)

-$1.7MUSD

-272.0M JPY

Net Income (TTM)

-$1.61MUSD

-257.0M JPY

EBITDA Margin

-57%

Profit Margin

-54%

PS Ratio

32.1

PB Ratio

3.7

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Biotechnology

CEO

Taro Ueno open_in_new

Employees

Founded

2015

Website

susmed.co.jp open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.1%	-2.2%	-9.2%	-1.3%	4.7%	8.5%	70%	-38%	-57%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4263 サスメド株式会社 ISIN: JP3319150003 Shares Out.: Shares Outstanding: 16.862M¹ Shares Float: 7.256M² TV: TradingView: TSE: 4263 SA: Stock Analysis: TYO: 4263 YF: Yahoo Finance: 4263.T GF: Google Finance: TYO: 4263 BA: Barron's: 4263 MS: Morningstar: XTKS: 4263	916 JPY	TV: TradingView: TSE: 4263 SA: Stock Analysis: TYO: 4263 YF: Yahoo Finance: 4263.T GF: Google Finance: TYO: 4263 BA: Barron's: 4263 MS: Morningstar: XTKS: 4263

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About SUSMED,Inc.

SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.

Similar Companies

Industry: Biotechnology (Japan)

Name	Market Cap (USD) diff.	PE	Country
GNI Group Ltd. TSE: 2160	$1.02B 162.8B JPY 957%	-	Japan
PeptiDream Inc. TSE: 4587	$929.38M 148.73B JPY 866%	-	Japan
Oncolys BioPharma Inc. TSE: 4588	$526.3M 84.22B JPY 447%	-	Japan
Cuorips Inc. TSE: 4894	$349.85M 55.99B JPY 264%	-	Japan
Innovacell Inc. TSE: 504A	$169.94M 27.19B JPY 77%	-	Japan
Stella Pharma Corp. TSE: 4888	$113.62M 18.18B JPY 18%	-	Japan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 189K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 166K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 50K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 46K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 45K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 44K%	37.2	Switzerland

chevron_leftBack